- Home
- STGW vs DNTH Comparison
STGW vs DNTH Comparison
Compare STGW & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STGW
- DNTH
- Stock Information
- Founded
- STGW 1980
- DNTH 2015
- Country
- STGW United States
- DNTH United States
- Employees
- STGW N/A
- DNTH N/A
- Industry
- STGW
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- STGW
- DNTH Health Care
- Exchange
- STGW Nasdaq
- DNTH Nasdaq
- Market Cap
- STGW 1.4B
- DNTH 1.5B
- IPO Year
- STGW N/A
- DNTH N/A
- Fundamental
- Price
- STGW $4.81
- DNTH $33.67
- Analyst Decision
- STGW Buy
- DNTH Strong Buy
- Analyst Count
- STGW 5
- DNTH 11
- Target Price
- STGW $8.17
- DNTH $65.22
- AVG Volume (30 Days)
- STGW 1.1M
- DNTH 585.5K
- Earning Date
- STGW 11-06-2025
- DNTH 11-07-2025
- Dividend Yield
- STGW N/A
- DNTH N/A
- EPS Growth
- STGW N/A
- DNTH N/A
- EPS
- STGW N/A
- DNTH N/A
- Revenue
- STGW $2,858,547,000.00
- DNTH $4,854,000.00
- Revenue This Year
- STGW $4.85
- DNTH N/A
- Revenue Next Year
- STGW $8.79
- DNTH N/A
- P/E Ratio
- STGW N/A
- DNTH N/A
- Revenue Growth
- STGW 9.37
- DNTH 17.87
- 52 Week Low
- STGW $4.03
- DNTH $13.37
- 52 Week High
- STGW $8.18
- DNTH $40.16
- Technical
- Relative Strength Index (RSI)
- STGW 37.75
- DNTH 46.12
- Support Level
- STGW $4.90
- DNTH $32.35
- Resistance Level
- STGW $5.20
- DNTH $34.50
- Average True Range (ATR)
- STGW 0.23
- DNTH 1.82
- MACD
- STGW -0.04
- DNTH -0.50
- Stochastic Oscillator
- STGW 1.33
- DNTH 20.92
About STGW Stagwell Inc.
Stagwell Inc is the challenger holding company built to transform marketing. It delivers scaled creative performance for the world's ambitious brands, connecting culture-moving creativity with a technology to harmonize the art and science of marketing. The company's segments include Integrated Agencies Network; Brand Performance Network; and Communications Network. It generates maximum revenue from the Integrated Agencies Network segment. Geographically, it derives a majority of its revenue from the United States.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.